[go: up one dir, main page]

AU2003299962A1 - Interferon drug therapy for the treatment of viral diseases and liver fibrosis - Google Patents

Interferon drug therapy for the treatment of viral diseases and liver fibrosis

Info

Publication number
AU2003299962A1
AU2003299962A1 AU2003299962A AU2003299962A AU2003299962A1 AU 2003299962 A1 AU2003299962 A1 AU 2003299962A1 AU 2003299962 A AU2003299962 A AU 2003299962A AU 2003299962 A AU2003299962 A AU 2003299962A AU 2003299962 A1 AU2003299962 A1 AU 2003299962A1
Authority
AU
Australia
Prior art keywords
treatment
drug therapy
liver fibrosis
viral diseases
interferon drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003299962A
Inventor
Lawrence M. Blatt
Henry H. Hsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Inc
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/006687 external-priority patent/WO2004078194A1/en
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of AU2003299962A1 publication Critical patent/AU2003299962A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003299962A 2003-02-28 2003-12-23 Interferon drug therapy for the treatment of viral diseases and liver fibrosis Abandoned AU2003299962A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2003/006687 WO2004078194A1 (en) 2003-02-28 2003-02-28 Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU2003225670 2003-02-28
PCT/US2003/032539 WO2004078193A1 (en) 2003-02-28 2003-10-14 Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU2003287145 2003-10-14
PCT/US2003/041369 WO2004078207A1 (en) 2003-02-28 2003-12-23 Interferon drug therapy for the treatment of viral diseases and liver fibrosis

Publications (1)

Publication Number Publication Date
AU2003299962A1 true AU2003299962A1 (en) 2004-09-28

Family

ID=32965092

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003299962A Abandoned AU2003299962A1 (en) 2003-02-28 2003-12-23 Interferon drug therapy for the treatment of viral diseases and liver fibrosis

Country Status (3)

Country Link
EP (1) EP1596883A1 (en)
AU (1) AU2003299962A1 (en)
WO (1) WO2004078207A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034764B2 (en) * 2003-10-21 2011-10-11 Medtronic Minimed, Inc. Modulation of SOCS expression in therapeutic regimens
CU23432B6 (en) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech STABILIZED FORMULATIONS CONTAINING GAMMA AND ALFA INTERFERONS IN POTENTIAL PROPORTIONS
CA2665438C (en) * 2006-10-04 2014-12-02 Tibotec Pharmaceuticals Ltd. Carboxamide 4-[(4-pyridyl)amino]pyrimidines useful as hcv inhibitors
WO2008101349A1 (en) * 2007-02-23 2008-08-28 Her Majesty The Queen, In Right Of Canada, As Repesented By The Minister Of National Defence Recombinant viral vectors for prevention and protection against alphavirus infection
MX2007009796A (en) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel containing pirfenidone.
MX2011007675A (en) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Process for manufacturing a pharmaceutical composition in a sustained-release tablet form containing pirfenidone and the application thereof in the regression of chronic renal failure, breast capsular contracture and liver fibrosis in humans.
MX346763B (en) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V SEMISOLID TOPIC COMPOSITION CONTAINING PYRFENIDONE AND DIALYL MODIFIED DISULFIDE OXIDE (ODD-M) TO ELIMINATE OR PREVENT ACNE.
CN103387601B (en) * 2012-05-11 2017-01-11 南开大学 Anti-dengue virus (DENV) heterocyclic peptide compounds and preparing methods and uses thereof
CN103421083A (en) * 2012-05-16 2013-12-04 南开大学 Anti-dengue virus heterocycle peptide compounds having 1,2,3-triazole structure, preparation method and use thereof
MX356551B (en) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Antiseptic, antiseborrheic, exfoliating composition for getting rid of or preventing acne.
GB201621728D0 (en) 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP1023901A4 (en) * 1997-10-13 2004-10-27 Otsuka Pharma Co Ltd Ameliorant for hepatitis c remedial effect and application thereof
US6103531A (en) * 1998-02-13 2000-08-15 Ohio State Research Foundation Methods of disrupting interferon signal transduction pathways

Also Published As

Publication number Publication date
EP1596883A1 (en) 2005-11-23
WO2004078207A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
AU2003225670A1 (en) Interferon drug therapy for the treatment of viral diseases and liver fibrosis
IL165860A0 (en) Administration of therapeutic viruses
AU2003220317A1 (en) Methods and drug delivery systems for the treatment of orofacial diseases
IL157364A0 (en) Therapeutic methods and agents for diseases associated with decreased expression of aop-1 gene or aop-1
IL169338A0 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
AU2003225281A1 (en) Materials and methods for prevention and treatment of rna viral diseases
AU2002329990A1 (en) Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
AU2003261251A1 (en) Methods of delivering therapeutic agents
AU2002322719A1 (en) Delivery of therapeutic capable agents
PL377854A1 (en) Nasal pharmaceutical formulations and methods of using the same
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
AU2003259381A1 (en) Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases
EP1572709A3 (en) Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
AU3009801A (en) Combinations of medicaments for treating viral diseases
AU5618501A (en) Dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
AU2003299962A1 (en) Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU2003273983A1 (en) Viral vectors and the use of the same for gene therapy
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
AU2002325169A1 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
AU2003256280A1 (en) Methods of delivering gene therapy agents
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
AU2003270540A1 (en) Treatment of cyclooxygenase-3 mediated diseases and disorders
AU2003240052A1 (en) Il-11 derivatives and therapeutic uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase